Le SIDA au Ghana (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa

Identifieur interne : 000049 ( PascalFrancis/Corpus ); précédent : 000048; suivant : 000050

Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa

Auteurs : Lara Isobel Compston ; CHENGYAO LI ; Francis Sarkodie ; Shirley Owusu-Ofori ; Ohene Opare-Sem ; Jean-Pierre Allain

Source :

RBID : Pascal:09-0421865

Descripteurs français

English descriptors

Abstract

Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/ AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P<0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P<0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P<0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P≤0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (>90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV).

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0146-6615
A02 01      @0 JMVIDB
A03   1    @0 J. med. virol.
A05       @2 81
A06       @2 11
A08 01  1  ENG  @1 Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa
A11 01  1    @1 ISOBEL COMPSTON (Lara)
A11 02  1    @1 CHENGYAO LI
A11 03  1    @1 SARKODIE (Francis)
A11 04  1    @1 OWUSU-OFORI (Shirley)
A11 05  1    @1 OPARE-SEM (Ohene)
A11 06  1    @1 ALLAIN (Jean-Pierre)
A14 01      @1 Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre @2 Cambridge @3 GBR @Z 1 aut. @Z 6 aut.
A14 02      @1 School of Biotechnology, Southern Medical University @2 Guangzhou @3 CHN @Z 2 aut.
A14 03      @1 Transfusion Medicine Unit, Komfo Anokye Teaching Hospital @2 Kumasi @3 GHA @Z 3 aut. @Z 4 aut.
A14 04      @1 Department of Medicine, Komfo Anokye Teaching Hospital @2 Kumasi @3 GHA @Z 5 aut.
A20       @1 1860-1868
A21       @1 2009
A23 01      @0 ENG
A43 01      @1 INIST @2 17422 @5 354000170266010030
A44       @0 0000 @1 © 2009 INIST-CNRS. All rights reserved.
A45       @0 1 p.1/4
A47 01  1    @0 09-0421865
A60       @1 P
A61       @0 A
A64 01  1    @0 Journal of medical virology
A66 01      @0 USA
C01 01    ENG  @0 Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/ AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P<0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P<0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P<0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P≤0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (>90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV).
C02 01  X    @0 002A05C10
C02 02  X    @0 002B05C02J
C02 03  X    @0 002A05C06
C03 01  X  FRE  @0 Virus immunodéficience humaine @2 NW @5 01
C03 01  X  ENG  @0 Human immunodeficiency virus @2 NW @5 01
C03 01  X  SPA  @0 Human immunodeficiency virus @2 NW @5 01
C03 02  X  FRE  @0 Herpesviridae @2 NW @5 02
C03 02  X  ENG  @0 Herpesviridae @2 NW @5 02
C03 02  X  SPA  @0 Herpesviridae @2 NW @5 02
C03 03  X  FRE  @0 Virus hépatite B @2 NW @5 03
C03 03  X  ENG  @0 Hepatitis B virus @2 NW @5 03
C03 03  X  SPA  @0 Hepatitis B virus @2 NW @5 03
C03 04  X  FRE  @0 Virus hépatite G @2 NW @5 04
C03 04  X  ENG  @0 Hepatitis G virus @2 NW @5 04
C03 04  X  SPA  @0 Hepatitis G virus @2 NW @5 04
C03 05  X  FRE  @0 Prévalence @5 05
C03 05  X  ENG  @0 Prevalence @5 05
C03 05  X  SPA  @0 Prevalencia @5 05
C03 06  X  FRE  @0 Epidémiologie @5 06
C03 06  X  ENG  @0 Epidemiology @5 06
C03 06  X  SPA  @0 Epidemiología @5 06
C03 07  X  FRE  @0 Ghana @2 NG @5 07
C03 07  X  ENG  @0 Ghana @2 NG @5 07
C03 07  X  SPA  @0 Ghana @2 NG @5 07
C03 08  X  FRE  @0 Afrique Ouest @2 NG @5 08
C03 08  X  ENG  @0 West Africa @2 NG @5 08
C03 08  X  SPA  @0 Africa occidental @2 NG @5 08
C03 09  X  FRE  @0 Hépatite virale B @5 09
C03 09  X  ENG  @0 Viral hepatitis B @5 09
C03 09  X  SPA  @0 Hepatitis vírica B @5 09
C03 10  X  FRE  @0 Parvovirus @2 NW @5 10
C03 10  X  ENG  @0 Parvovirus @2 NW @5 10
C03 10  X  SPA  @0 Parvovirus @2 NW @5 10
C03 11  X  FRE  @0 Afrique subsaharienne @2 NG @5 11
C03 11  X  ENG  @0 Sub-Saharan Africa @2 NG @5 11
C03 11  X  SPA  @0 Africa subsahariana @2 NG @5 11
C03 12  X  FRE  @0 SIDA @5 14
C03 12  X  ENG  @0 AIDS @5 14
C03 12  X  SPA  @0 SIDA @5 14
C03 13  X  FRE  @0 Immunodéficit @5 15
C03 13  X  ENG  @0 Immune deficiency @5 15
C03 13  X  SPA  @0 Inmunodeficiencia @5 15
C07 01  X  FRE  @0 Lentivirus @2 NW
C07 01  X  ENG  @0 Lentivirus @2 NW
C07 01  X  SPA  @0 Lentivirus @2 NW
C07 02  X  FRE  @0 Retroviridae @2 NW
C07 02  X  ENG  @0 Retroviridae @2 NW
C07 02  X  SPA  @0 Retroviridae @2 NW
C07 03  X  FRE  @0 Virus @2 NW
C07 03  X  ENG  @0 Virus @2 NW
C07 03  X  SPA  @0 Virus @2 NW
C07 04  X  FRE  @0 Orthohepadnavirus @2 NW
C07 04  X  ENG  @0 Orthohepadnavirus @2 NW
C07 04  X  SPA  @0 Orthohepadnavirus @2 NW
C07 05  X  FRE  @0 Hepadnaviridae @2 NW
C07 05  X  ENG  @0 Hepadnaviridae @2 NW
C07 05  X  SPA  @0 Hepadnaviridae @2 NW
C07 06  X  FRE  @0 Flavivirus @2 NW
C07 06  X  ENG  @0 Flavivirus @2 NW
C07 06  X  SPA  @0 Flavivirus @2 NW
C07 07  X  FRE  @0 Flaviviridae @2 NW
C07 07  X  ENG  @0 Flaviviridae @2 NW
C07 07  X  SPA  @0 Flaviviridae @2 NW
C07 08  X  FRE  @0 Afrique @2 NG
C07 08  X  ENG  @0 Africa @2 NG
C07 08  X  SPA  @0 Africa @2 NG
C07 09  X  FRE  @0 Virose
C07 09  X  ENG  @0 Viral disease
C07 09  X  SPA  @0 Virosis
C07 10  X  FRE  @0 Infection
C07 10  X  ENG  @0 Infection
C07 10  X  SPA  @0 Infección
C07 11  X  FRE  @0 Parvovirinae @2 NW
C07 11  X  ENG  @0 Parvovirinae @2 NW
C07 11  X  SPA  @0 Parvovirinae @2 NW
C07 12  X  FRE  @0 Parvoviridae @2 NW
C07 12  X  ENG  @0 Parvoviridae @2 NW
C07 12  X  SPA  @0 Parvoviridae @2 NW
C07 13  X  FRE  @0 Immunopathologie @5 16
C07 13  X  ENG  @0 Immunopathology @5 16
C07 13  X  SPA  @0 Inmunopatología @5 16
C07 14  X  FRE  @0 Pathologie de l'appareil digestif @5 17
C07 14  X  ENG  @0 Digestive diseases @5 17
C07 14  X  SPA  @0 Aparato digestivo patología @5 17
C07 15  X  FRE  @0 Pathologie du foie @5 18
C07 15  X  ENG  @0 Hepatic disease @5 18
C07 15  X  SPA  @0 Hígado patología @5 18
N21       @1 306
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 09-0421865 INIST
ET : Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa
AU : ISOBEL COMPSTON (Lara); CHENGYAO LI; SARKODIE (Francis); OWUSU-OFORI (Shirley); OPARE-SEM (Ohene); ALLAIN (Jean-Pierre)
AF : Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre/Cambridge/Royaume-Uni (1 aut., 6 aut.); School of Biotechnology, Southern Medical University/Guangzhou/Chine (2 aut.); Transfusion Medicine Unit, Komfo Anokye Teaching Hospital/Kumasi/Ghana (3 aut., 4 aut.); Department of Medicine, Komfo Anokye Teaching Hospital/Kumasi/Ghana (5 aut.)
DT : Publication en série; Niveau analytique
SO : Journal of medical virology; ISSN 0146-6615; Coden JMVIDB; Etats-Unis; Da. 2009; Vol. 81; No. 11; Pp. 1860-1868; Bibl. 1 p.1/4
LA : Anglais
EA : Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/ AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P<0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P<0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P<0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P≤0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (>90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV).
CC : 002A05C10; 002B05C02J; 002A05C06
FD : Virus immunodéficience humaine; Herpesviridae; Virus hépatite B; Virus hépatite G; Prévalence; Epidémiologie; Ghana; Afrique Ouest; Hépatite virale B; Parvovirus; Afrique subsaharienne; SIDA; Immunodéficit
FG : Lentivirus; Retroviridae; Virus; Orthohepadnavirus; Hepadnaviridae; Flavivirus; Flaviviridae; Afrique; Virose; Infection; Parvovirinae; Parvoviridae; Immunopathologie; Pathologie de l'appareil digestif; Pathologie du foie
ED : Human immunodeficiency virus; Herpesviridae; Hepatitis B virus; Hepatitis G virus; Prevalence; Epidemiology; Ghana; West Africa; Viral hepatitis B; Parvovirus; Sub-Saharan Africa; AIDS; Immune deficiency
EG : Lentivirus; Retroviridae; Virus; Orthohepadnavirus; Hepadnaviridae; Flavivirus; Flaviviridae; Africa; Viral disease; Infection; Parvovirinae; Parvoviridae; Immunopathology; Digestive diseases; Hepatic disease
SD : Human immunodeficiency virus; Herpesviridae; Hepatitis B virus; Hepatitis G virus; Prevalencia; Epidemiología; Ghana; Africa occidental; Hepatitis vírica B; Parvovirus; Africa subsahariana; SIDA; Inmunodeficiencia
LO : INIST-17422.354000170266010030
ID : 09-0421865

Links to Exploration step

Pascal:09-0421865

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa</title>
<author>
<name sortKey="Isobel Compston, Lara" sort="Isobel Compston, Lara" uniqKey="Isobel Compston L" first="Lara" last="Isobel Compston">Lara Isobel Compston</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Chengyao Li" sort="Chengyao Li" uniqKey="Chengyao Li" last="Chengyao Li">CHENGYAO LI</name>
<affiliation>
<inist:fA14 i1="02">
<s1>School of Biotechnology, Southern Medical University</s1>
<s2>Guangzhou</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sarkodie, Francis" sort="Sarkodie, Francis" uniqKey="Sarkodie F" first="Francis" last="Sarkodie">Francis Sarkodie</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Owusu Ofori, Shirley" sort="Owusu Ofori, Shirley" uniqKey="Owusu Ofori S" first="Shirley" last="Owusu-Ofori">Shirley Owusu-Ofori</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Opare Sem, Ohene" sort="Opare Sem, Ohene" uniqKey="Opare Sem O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Department of Medicine, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Allain, Jean Pierre" sort="Allain, Jean Pierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">09-0421865</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0421865 INIST</idno>
<idno type="RBID">Pascal:09-0421865</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000049</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa</title>
<author>
<name sortKey="Isobel Compston, Lara" sort="Isobel Compston, Lara" uniqKey="Isobel Compston L" first="Lara" last="Isobel Compston">Lara Isobel Compston</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Chengyao Li" sort="Chengyao Li" uniqKey="Chengyao Li" last="Chengyao Li">CHENGYAO LI</name>
<affiliation>
<inist:fA14 i1="02">
<s1>School of Biotechnology, Southern Medical University</s1>
<s2>Guangzhou</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sarkodie, Francis" sort="Sarkodie, Francis" uniqKey="Sarkodie F" first="Francis" last="Sarkodie">Francis Sarkodie</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Owusu Ofori, Shirley" sort="Owusu Ofori, Shirley" uniqKey="Owusu Ofori S" first="Shirley" last="Owusu-Ofori">Shirley Owusu-Ofori</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Opare Sem, Ohene" sort="Opare Sem, Ohene" uniqKey="Opare Sem O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Department of Medicine, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Allain, Jean Pierre" sort="Allain, Jean Pierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>AIDS</term>
<term>Epidemiology</term>
<term>Ghana</term>
<term>Hepatitis B virus</term>
<term>Hepatitis G virus</term>
<term>Herpesviridae</term>
<term>Human immunodeficiency virus</term>
<term>Immune deficiency</term>
<term>Parvovirus</term>
<term>Prevalence</term>
<term>Sub-Saharan Africa</term>
<term>Viral hepatitis B</term>
<term>West Africa</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Virus immunodéficience humaine</term>
<term>Herpesviridae</term>
<term>Virus hépatite B</term>
<term>Virus hépatite G</term>
<term>Prévalence</term>
<term>Epidémiologie</term>
<term>Ghana</term>
<term>Afrique Ouest</term>
<term>Hépatite virale B</term>
<term>Parvovirus</term>
<term>Afrique subsaharienne</term>
<term>SIDA</term>
<term>Immunodéficit</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/ AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P<0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P<0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P<0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P≤0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (>90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV).</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0146-6615</s0>
</fA01>
<fA02 i1="01">
<s0>JMVIDB</s0>
</fA02>
<fA03 i2="1">
<s0>J. med. virol.</s0>
</fA03>
<fA05>
<s2>81</s2>
</fA05>
<fA06>
<s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>ISOBEL COMPSTON (Lara)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>CHENGYAO LI</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>SARKODIE (Francis)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>OWUSU-OFORI (Shirley)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>OPARE-SEM (Ohene)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>ALLAIN (Jean-Pierre)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>School of Biotechnology, Southern Medical University</s1>
<s2>Guangzhou</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Medicine, Komfo Anokye Teaching Hospital</s1>
<s2>Kumasi</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20>
<s1>1860-1868</s1>
</fA20>
<fA21>
<s1>2009</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>17422</s2>
<s5>354000170266010030</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>09-0421865</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/ AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P<0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P<0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P<0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P≤0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (>90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV).</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B05C02J</s0>
</fC02>
<fC02 i1="03" i2="X">
<s0>002A05C06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Herpesviridae</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Herpesviridae</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Herpesviridae</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Virus hépatite B</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Virus hépatite G</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Hepatitis G virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Hepatitis G virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Prévalence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Prevalence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Prevalencia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Epidémiologie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Epidemiology</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Epidemiología</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Ghana</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Ghana</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Ghana</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Afrique Ouest</s0>
<s2>NG</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>West Africa</s0>
<s2>NG</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Africa occidental</s0>
<s2>NG</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Hépatite virale B</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Viral hepatitis B</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Hepatitis vírica B</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Parvovirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Parvovirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Parvovirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Afrique subsaharienne</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Sub-Saharan Africa</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Africa subsahariana</s0>
<s2>NG</s2>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>SIDA</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>AIDS</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>SIDA</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Immunodéficit</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Immune deficiency</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Inmunodeficiencia</s0>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Afrique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Africa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Africa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Parvovirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Parvovirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Parvovirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Parvoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Parvoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Parvoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="13" i2="X" l="FRE">
<s0>Immunopathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG">
<s0>Immunopathology</s0>
<s5>16</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA">
<s0>Inmunopatología</s0>
<s5>16</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE">
<s0>Pathologie de l'appareil digestif</s0>
<s5>17</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG">
<s0>Digestive diseases</s0>
<s5>17</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA">
<s0>Aparato digestivo patología</s0>
<s5>17</s5>
</fC07>
<fC07 i1="15" i2="X" l="FRE">
<s0>Pathologie du foie</s0>
<s5>18</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG">
<s0>Hepatic disease</s0>
<s5>18</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA">
<s0>Hígado patología</s0>
<s5>18</s5>
</fC07>
<fN21>
<s1>306</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 09-0421865 INIST</NO>
<ET>Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa</ET>
<AU>ISOBEL COMPSTON (Lara); CHENGYAO LI; SARKODIE (Francis); OWUSU-OFORI (Shirley); OPARE-SEM (Ohene); ALLAIN (Jean-Pierre)</AU>
<AF>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre/Cambridge/Royaume-Uni (1 aut., 6 aut.); School of Biotechnology, Southern Medical University/Guangzhou/Chine (2 aut.); Transfusion Medicine Unit, Komfo Anokye Teaching Hospital/Kumasi/Ghana (3 aut., 4 aut.); Department of Medicine, Komfo Anokye Teaching Hospital/Kumasi/Ghana (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of medical virology; ISSN 0146-6615; Coden JMVIDB; Etats-Unis; Da. 2009; Vol. 81; No. 11; Pp. 1860-1868; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<EA>Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/ AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P<0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P<0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P<0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P≤0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (>90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV).</EA>
<CC>002A05C10; 002B05C02J; 002A05C06</CC>
<FD>Virus immunodéficience humaine; Herpesviridae; Virus hépatite B; Virus hépatite G; Prévalence; Epidémiologie; Ghana; Afrique Ouest; Hépatite virale B; Parvovirus; Afrique subsaharienne; SIDA; Immunodéficit</FD>
<FG>Lentivirus; Retroviridae; Virus; Orthohepadnavirus; Hepadnaviridae; Flavivirus; Flaviviridae; Afrique; Virose; Infection; Parvovirinae; Parvoviridae; Immunopathologie; Pathologie de l'appareil digestif; Pathologie du foie</FG>
<ED>Human immunodeficiency virus; Herpesviridae; Hepatitis B virus; Hepatitis G virus; Prevalence; Epidemiology; Ghana; West Africa; Viral hepatitis B; Parvovirus; Sub-Saharan Africa; AIDS; Immune deficiency</ED>
<EG>Lentivirus; Retroviridae; Virus; Orthohepadnavirus; Hepadnaviridae; Flavivirus; Flaviviridae; Africa; Viral disease; Infection; Parvovirinae; Parvoviridae; Immunopathology; Digestive diseases; Hepatic disease</EG>
<SD>Human immunodeficiency virus; Herpesviridae; Hepatitis B virus; Hepatitis G virus; Prevalencia; Epidemiología; Ghana; Africa occidental; Hepatitis vírica B; Parvovirus; Africa subsahariana; SIDA; Inmunodeficiencia</SD>
<LO>INIST-17422.354000170266010030</LO>
<ID>09-0421865</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000049 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000049 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0421865
   |texte=   Prevalence of Persistent and Latent Viruses in Untreated Patients Infected With HIV-1 From Ghana, West Africa
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024